Research at Ohio State University, funded by the National Institutes of Health, has found that tocotrienols – found abundantly in Malaysian Palm Fruit Oil, may either slow the progression of liver disease or enable a patient to cut back on therapies, which are often not well tolerated. This news comes at a time when there’s a lot of talk about the most common cause of chronic liver disease in the U.S.: nonalcoholic fatty liver disease (NAFLD). Some experts have called this an “under-diagnosed epidemic”. It is observed most frequently in developed countries where people have a sedentary lifestyle and high-calorie, high-fat diets.
Nonalcoholic fatty liver disease is a term that describes the accumulation of fat in the liver of people who drink little or no alcohol. There is evidence indicating that NAFLD increases the risk of heart disease in children who are overweight or obese.
For most people, NAFLD causes no outward signs, symptoms or complications. But some experts estimate that 90 percent of people who are obese and those who have been diagnosed with type 2 diabetes may also have this fatty liver disease. For some people, it may cause inflammation and scarring that may lead to a form of hepatitis and may lead to liver failure. Some possible risk factors include: family history, being middle-aged and overweight or obese, having high cholesterol or trigylerides, and having diabetes or prediabetes.
There is currently no drug that can effectively cure or treat NAFLD.
Read more about the exciting research involving Malaysian palm fruit oil-derived tocotrienols and liver health.